PEDIATRIC PULMONOLOGY, vol.55, no.9, pp.2302-2306, 2020 (Journal Indexed in SCI)
Article / Article
Title of Journal :
cystic fibrosis, modulator drugs, national registry, TEZACAFTOR-IVACAFTOR
Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.